Belgian biotherapeutics firm AgomAb inks Series A funding

AgomAb, a Belgian biotherapeutics company, has secured 21 million euros in Series A funding. V-Bio Ventures and Advent France Biotechnology led the round with participation from Boehringer Ingelheim Venture Fund, Omnes and Pontifax.

Source: Press Release